Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Melanoma 8Multiple Myeloma 6Hematologic Neoplasms 6Lymphoma 5Neoplasm Metastasis 4Thyroid Neoplasms 2Glioma 2Cholangiocarcinoma 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Bile Duct Neoplasms 2Uveal Melanoma 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Cancer, Papillary 1Stomach Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neurofibromatosis 1 1Lung Neoplasms 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myeloid, Acute 1Klatskin Tumor 1Hemangioendothelioma, Epithelioid 1Glioblastoma 1

Interventions

Magnetic Resonance Spectroscopy 6Iodine-131 3Fluorodeoxyglucose F18 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3Trastuzumab 2Sorafenib 2Radiotherapy 2trametinib 1tipifarnib 1tanespimycin 1sargramostim 1romidepsin 1omipalisib 1gallium Ga 68 dotatate 1cediranib 1cabozantinib 1aldesleukin 1aflibercept 1Vorinostat 1Triiodothyronine 1Thyrotropin Alfa 1Tamoxifen 1Sunitinib 1Specimen Handling 1Rosiglitazone 1Ritonavir 1Radiofrequency Ablation 1Pharmacogenomic Testing 1Nivolumab 1Lenalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Thyroid Cancer, Papillary × trametinib × Clear all
NCT02152995 2026-04-13

Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
34 enrolled 18 charts
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡